Cancers & treatments·Regimen libraryLater line

Mirvetuximab soravtansine

Checked 2026-09-09

Folate receptor alpha-high platinum-resistant ovarian cancer, 1-3 prior lines

One cycle

every 21 days

21-day cycle, until progressionIntravenous

Components

Drug	Dose	Route	Days	Note
Mirvetuximab soravtansine ADC	6 mg/kg adjusted ideal body weight	IV	D1

Cycles

until progression

21-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Ocular toxicity: baseline and periodic eye examination, steroid and lubricating eye drops.

Used in

Trials

MIRASOL / GOG-3045

Products

Mirvetuximab soravtansine

Source

MIRASOL, NEJM 2023

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Relapsed SCLC; platinum-resistant ovarian or cervical cancer

Metastatic germ cell tumour: 3 cycles good risk, 4 cycles intermediate or poor risk

every 21 days × 3

Carboplatin + paclitaxel

Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC

every 21 days × 6

Carboplatin + paclitaxel + bevacizumab, then bevacizumab maintenance

Stage III-IV ovarian cancer, especially with residual disease or ascites

every 21 days × 6

Weekly paclitaxel

Platinum-resistant ovarian cancer (with or without bevacizumab); metastatic breast cancer

Pegylated liposomal doxorubicin

Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma

Olaparib maintenance

Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum

every 28 days × 2

Niraparib maintenance

Newly diagnosed advanced ovarian cancer after platinum response, regardless of BRCA status

every 28 days × 3

All regimens Weekly cisplatin chemoradiation (with pembrolizumab for high-risk disease) →